AI-assisted, human-published
01/28/2025 /Funding Events
Atalanta Therapeutics Secures $97M for Neurological Disease Treatments
Atalanta Therapeutics concludes Series B financing to support Phase 1 clinical trials for RNAi therapies targeting KCNT1-related epilepsy and Huntington’s disease.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com